PATENT CLAIM ANALYSIS

Application Number: 16062004
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "314000"]

Abstract:
The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.

Claim (Index 17):
The method of  claim 16 , wherein the daily dose of X4P-001, or a pharmaceutically acceptable salt thereof, is from about 200 mg to about 1200 mg.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 94.0
- Lexical Diversity: 1.29787
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16065470', '15567838', '15304394', '14646518', '14647939']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6930839691420688
- 35 USC 102 Novelty (BERT): 0.5164542206579118
- Combined Prediction Score: 0.6754209942936531
- Mean Citation Score: 182.070182
- Max Citation Score: 190.87717
- Similarity Product: 111.16653843925836

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test